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1. In the labyrinth of multiple sclerosis
Multiple sclerosis (MS) remains a crucial unsolved problem in the field of neu-
rosciences, being also a serious cause of suffering for millions of patients worldwide 
affecting the quality of life, the personal and social economy, and the psychoso-
matic homeostasis substantially in the majority of the patients.
The etiopathological background of the disease, which is a progressive inflam-
mation of the CNS [1, 2], inducing demyelination in the white matter and degen-
erative alterations in the gray matter in various areas of the brain hemispheres, 
the cerebellum, the brain stem, and the spinal cord, may provoke a multitude of 
polymorphic clinical phenomena inducing a variable type of physical, mental, and 
social disability in the suffering people [3, 4].
The incidence of MS varies considerably across geographic regions, with high 
rates in high latitude and low in the tropical zone, affecting three times more 
women than men at any age, though the climax is between 20 and 40 years. 
Approximately 2.5 million people in the world suffer from multiple sclerosis nowa-
days, and 700,000 among them are registered in Europe [5–7].
Many genetic factors, MHC and non-MHC, may play an important role in the 
innate immune mechanisms and in the modulation of the immune system under 
the influence of the many exterior environmental risk factors and viral infections 
[8, 9]. Among the viruses, the infection with Epstein–Barr virus (EBV), which is 
a common human herpes virus, seems to have a considerable association with the 
incidence of MS, particularly among pediatric patients [10–12].
A large number of patients have from onset the experience of relapses and 
remissions of the various neurological phenomena, lasting for many years, whereas 
a substantial number of untreated patients face the tragedy of the continuous 
deterioration of their physical and mental condition, resulting in a serious irrevers-
ible disability eventually, though primary progressive forms starting from the onset 
of the disease may also occur in approximately 10–15% of patients [13, 14].
Energy failure is obviously the substantial cause of the functional impairment 
in the majority of patients who suffer from multiple sclerosis. That cause is reason-
ably associated with demyelination, neuronal degeneration, and axonal loss, based 
on a wide spectrum of innate autoimmune mechanisms, inflammatory reactions, 
mitochondrial dysfunction, cytokine interactions, intracellular and interstitial 
edema, and perivascular cell reactions [15, 16].
2. The multiform suffering
The multiform clinical manifestations of the disease vary from person to 
person, from time to time, from age to age, and most of them are unstable and 
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changeable in the majority of the cases even from the initial stages of the disease. 
Vertigo, nausea, vomiting, hiccups, motor deficits, tremors, dysarthria, cutaneous 
sensory deficits, sensory phenomena from mucosae, cerebellar dysfunction, gait 
instability, diplopia, vision impairment, visual field defects, dyschromatopsia, 
phosphenes, hearing impairment, painful conditions, neuralgia of the trigeminal 
nerve, autonomic dysfunction, sphincter insufficiency, fatigue, and cognitive 
decline, such as episodic memory deficits and impaired visuospacial estimation, 
emerging early in the disease compose a part of the frequently resizing pattern of 
the disease [17].
Particularly, cognitive decline, which would be attributed to the association of 
gray and white matter lesions [18], in addition to disconnection and dissociation 
syndrome, is frequently underestimated in the initial stages of the disease, neces-
sitating neuropsychological evaluation by properly designed tools for MS patients 
[19]. In fact, cognitive phenomena are evident in the same degree of severity during 
all the stages of the disease, concerning all clinical subtypes [20, 21]. Cognitive 
rehabilitation, which is essential for the improvement of the quality of life of the 
patients, may include various methods and technics enabling the patients to over-
come common problems of everyday life and to cope harmoniously with the disease 
burden, improving skills and capacities on the basis of the neuronal plasticity and 
the principle of functional reorganization of the brain [22, 23].
Language disorders are not rare phenomena in patients who suffer from MS [24]. 
The naming deficit, semantic paraphasia, impaired verbal fluency, grammar and 
syntax deficits, and the loss of high-level language skills necessitate the appropriate 
speech therapy [25].
3. Searching for the truth
Diagnostic criteria for multiple sclerosis have been proposed and introduced 
for many years and have been revised over times [26]. Most of them may simply 
facilitate the approach of the diagnosis of the disease. In general, the clinical estima-
tion of the patients and the incorporation of data from the paraclinical investiga-
tion, especially from MRI [27], diffusion imaging, resting state functional MRI, 
magnetic resonance spectroscopy, evoked potentials, optical coherence tomography 
(OCT) [28], OCT angiography, and immunological analysis of the CSF, may lead to 
a prompt diagnosis of the disease even in patients with atypical clinical manifesta-
tions and marked course heterogeneity [29, 30].
In the cases that clinical and neuroimaging data are atypical or inadequate for 
posing the diagnosis of MS, the findings of oligoclonal band and immunoglobulin 
G (IgG) level in the cerebrospinal fluid analysis, in correlation with the serum data, 
would be a strong argument of intrathecal inflammation, advocating in favor of the 
diagnosis of MS [31].
However, in the differential diagnosis of multiple sclerosis, a substantial number 
of other conditions mimicking the clinical manifestations of the disease should be 
under consideration [32]. Among them, the neuromyelitis optica spectrum disorder 
(Devic’s disease) would be differentially diagnosed on the basis of anti-aquaporin 4 
antibody (AQP4-IgG) [33], the acute disseminated encephalomyelitis (ADEM) on 
the basis of the clinical profile and the neuroimaging data [34], the MOG antibody 
disease on the basis of the level of MOG antibodies [35], and the antiphospholipid 
syndrome by the detection of lupus anticoagulant and anticardiolipin antibodies 
[36]. In addition systemic lupus erythematosus, small vessel disease, and Susac’s 
syndrome have a substantial place in the expanded spectrum of the differential 
diagnosis of MS [37].
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Disease activity is usually estimated by the clinical relapses and the MRI findings 
of contrast-enhanced lesions, enabling the detection of new lesions on T2-weighted 
images. However, a reasonable criticism and a periodic reevaluation of the adopted 
diagnostic criteria would be of substantial importance for the accuracy of the 
prompt diagnosis of MS [38, 39].
4. Perspectives on resolution
There is no definite targeted therapeutic approach for MS [40–42]. The appli-
cation of many current treatments aims at ameliorating the quality of life of the 
patients by reducing the disability progression and stabilizing the clinical condition 
of the patients [43].
The introduction of interferon in 1993 opened the horizons of many potential 
therapeutic options of various efficacy and side effects, which turned to raise many 
reasonable controversies from the viewpoint of the heterogeneity of the disease, the 
obscure etiopathological background, and the complexity of the pathophysiological 
mechanisms [44].
An efficient therapeutic strategy should be based on a clear knowledge of 
the pathogenetic mechanisms of the disease. The investigation of the role of the 
myeloid cells and the infiltration of the CNS by peripheral lymphoid and myeloid 
cells may be crucial for a deeper understanding of the progression of the disease and 
the chronicity of the clinical phenomena [45, 46].
Novel therapeutical attempts aiming at modulating the activities and reactions 
of myeloid cells might be hopeful in treating MS patients at the initial stages of the 
disease. In addition the application of autologous EBV-specific T cell therapy may 
improve the clinical condition of the patients, ameliorating consequently the qual-
ity of life in a substantial number of them [47–49].
Non-pharmacological therapies [50], such as appropriate diet [51], proper 
environment, physical exercise [52], psychological relaxation [53] and progres-
sive muscle relaxation therapy (PMRT), psychotherapy [54], cognitive behavioral 
therapy [55], music therapy [56], and emotional, social, and spiritual support [57] 
may also play a considerable beneficial role in the amelioration of the quality of life 
in the large majority of the patients.
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